Meeting
2023 ASCO Genitourinary Cancers Symposium
Pathologic response with neoadjuvant chemotherapy, immunotherapy, and chemo-immunotherapy for muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis.
Authors
Ahsan Ayaz
Mayo Clinic, Karachi, AZ
Ahsan Ayaz , Syed Arsalan Ahmed Naqvi , Nikita Tripathi , Hafsah Ijaz , Sajid Ahmad Mir , Parminder Singh , Syed A. Hussain , Guru P. Sonpavde , Bradley Alexander McGregor , Alan Haruo Bryce , Irbaz Bin Riaz , Praful Ravi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 531)
DOI
10.1200/JCO.2023.41.6_suppl.531
Abstract #
531
Poster Bd #
L14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Quantifying the absolute benefit of neoadjuvant chemotherapy followed by definitive therapy in patients with muscle-invasive bladder cancer: A systematic review and meta-analysis.
First Author: Waleed Ikram
Poster
2022 ASCO Genitourinary Cancers Symposium
A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer.
First Author: Waleed Ikram
Poster
2020 ASCO Virtual Scientific Program
Pathological response rates and quality of life outcomes of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle-invasive transitional cell carcinoma of the urinary bladder.
First Author: Amarnath Challapalli
Poster
2024 ASCO Breakthrough
Efficacy and biomarker analysis of neoadjuvant disitamab vedotin combined with immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study.
First Author: Jiao Hu